Barclays analyst Gena Wang lowered the firm’s price target on Bluebird Bio (BLUE) to $2 from $4 and keeps an Overweight rating on the shares. The company reported a Q3 revenue miss due to the timing of infusions, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE: